EUVIMEDEUVIMED entdecken
Crossref

Lacrimal gland targeted therapies for refractory epiphora: quantitative changes in the gland activity

Swati Singh, Nandini Bothra, Mohammad Javed Ali

Orbit · 2024

DOI: 10.1080/01676830.2023.2204493 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Orbit, 2024. Verfasst von Swati Singh und 2 weiteren Autor:innen. Beteiligte Einrichtung: Institute for Clinical and Functional Anatomy, Friedrich Alexander University, Erlangen, Germany. Hauptthemen laut MEDLINE: Lacrimal Apparatus, Botulinum Toxins, Type A, Lacrimal Apparatus Diseases. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 14 Literaturangaben. Gefördert von: Science and Engineering Research Board.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: To investigate the effect of botulinum toxin (BTX) and partial orbital lobe dacryoadenectomy (POLD) on the main lacrimal gland functions using the direct assessment of its secretory activity. METHODS: A pilot study involving 14 subjects (mean age, 42.16 years) with proximal bicanalicular block (n = 9) or complete punctal effacement (n = 5) received either intraglandular 2.5 units of BTX (n = 7) or underwent the POLD procedure (n = 7). Dynamic assessment of tear secretion from the palpebral lobes was performed as per standard protocols. The parameters studied included Schirmer I, changes in the glandular outflow, and the neurosensory secretory lag. RESULTS: Schirmer I values showed a mean reduction of 5.25 mm (range, 2-8 mm) following BTX injection, and mean tear flow decreased from 1.46 μl/min to 1.11 μl/min (P = 0.15). The POLD group showed a significant mean reduction of 0.45 μl/min in mean tear flow at 1 month (P = 0.03) and 0.32 μl/min at 3 months of follow-up (P = 0.20). However, there was no statistically significant change of the Schirmer values in the POLD group at 3 months. CONCLUSION: Direct assessment of lacrimal gland function can be used to monitor changes following the gland therapies. Although POLD shows a significant reduction in short term, significant surgical improvisation would be needed for it to be effective in long term. A larger study is ongoing to further our understanding.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lacrimal ApparatusBotulinum Toxins, Type ALacrimal Apparatus DiseasesHumansAdultPilot ProjectsTears

Stichwörter der Autor:innen

Lacrimal glandbotulinum toxincanalicular obstructiondacryoadenectomyepiphora

Substanzen

Botulinum Toxins, Type A

Autor:innen und Institutionen

  • Institute for Clinical and Functional Anatomy, Friedrich Alexander University, Erlangen, Germany.
  • Ophthalmic Plastic Surgery Services, LV Prasad Eye Institute, Hyderabad, India.
  • Govindram Seksaria Institute of Dacryology, LV Prasad Eye Institute, Hyderabad, India.

Förderung

  • Science and Engineering Research Board

Zitieren

APA

Singh, S., Bothra, N., & Ali, M. J. (2024). Lacrimal gland targeted therapies for refractory epiphora: quantitative changes in the gland activity. Orbit. https://doi.org/10.1080/01676830.2023.2204493

Vancouver

Singh S, Bothra N, Ali MJ. Lacrimal gland targeted therapies for refractory epiphora: quantitative changes in the gland activity. Orbit. 2024. doi:10.1080/01676830.2023.2204493

BibTeX
@article{Singh2024,
  author = {Singh, Swati and Bothra, Nandini and Ali, Mohammad Javed},
  title = {Lacrimal gland targeted therapies for refractory epiphora: quantitative changes in the gland activity},
  journal = {Orbit},
  year = {2024},
  doi = {10.1080/01676830.2023.2204493}
}
Kostenlos starten →